VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a report released on Wednesday morning. The firm issued a sell rating on the stock.

Separately, Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a research note on Friday, August 16th.

VolitionRx Trading Down 2.1 %

Shares of VNRX opened at $0.79 on Wednesday. The firm’s 50-day moving average is $0.69 and its two-hundred day moving average is $0.68. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.23. The firm has a market capitalization of $73.57 million, a P/E ratio of -2.21 and a beta of 1.10.

Hedge Funds Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC raised its stake in VolitionRx Limited (NYSE:VNRX) by 78.8% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent quarter. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.